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ESI-IT MS, Electrospray ionization-ion trap mass spectrometry;  




In the classical major histocompatibility complex (MHC) class I antigen 
presentation pathway, antigenic peptides derived from viral proteins by multiple 
proteolytic cleavages are transported to the endoplasmic reticulum lumen and 
then are exposed to aminopeptidase activity. In the present study, a long MHC 
class I natural ligand recognized by cytotoxic T lymphocytes was used to study 
the kinetics of degradation by aminopeptidase. The in vitro data indicate that 
this N-extended peptide is efficiently trimmed to a 9mer, unless its binding to the 




In the cytosol, newly synthesized viral proteins are proteolytically 
processed prior to MHC class I heavy chain-β2m-peptide complex formation in 
the lumen of the endoplasmic reticulum (ER) (1). In addition to the proteasome, 
a number of alternative proteases that contribute to endogenous antigen 
processing have been identified (reviewed in (2)). Usually, MHC class I 
molecules bind peptides of 8-10 residues by interaction of the peptide anchor 
residues with the pockets of the binding groove of the presenting molecule (3), 
(4). Some peptides can be directly produced in their final form, whereas others 
are generated as precursors (5). These precursor peptides must generally have 
the correct C-terminus of the final antigenic peptides (6). In contrast, the 
extraordinarily diverse pool of substrates  for TAP transport do not yet have 
precise N-termini and therefore require editing and customization before they 
yield the final peptide-MHC complexes. The ER-resident enzyme that trims the 
N-terminally extended residues of peptide precursors to their final length has 
been identified as the ER aminopeptidase associated with antigen processing 
(ERAAP) in mice (7) and ER aminopeptidase 1 (ERAP1) (8), (9) and 
aminopeptidase 2 (ERAP2) (10) in humans.  
In a classical paper from the early 1990s, Falk et al. (11) proposed six 
different and mutually exclusive models to explain the interactions among 
precursor peptides, MHC molecules, and an unknown trimming peptidase, later 
named ERAAP. Currently, the mechanism of ERAAP function is still a 
controversial issue, with two models supported by different studies. First, the 
"molecular ruler" mechanism (12) proposes the binding of both N- and C-
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terminal residues of a 9-16 aa substrate to the enzyme. The lateral chain of the 
C-terminus residue would interact with a hydrophobic pocket away from the 
active site. The N-terminal residues are accessible to the active site, and the 
enzyme trims longer precursors in a nonprocessive manner, after which MHC 
class I molecules can bind the epitopes. A later study (13), indicates that 
ERAP1 also recognizes internal sequence of the peptide. The second or 
“template” model (14) implies that peptides with a proper MHC I motif but 
retaining the too-long N-terminus would bind to MHC molecules and would then 
be trimmed by ERAAP; in this way, the superfluous amino acids at the N-
terminus would be cut away to generate the minimal epitope. 
A previous study investigated natural peptides endogenously processed 
from the HIV gp160 glycoprotein in living cells that express murine H-2d class I 
molecules. Unexpectedly, the natural situation was more complex than a single 
type of peptide/MHC class I complex. A nested set of three abundant and 
equally antigenic peptides that differed in the N-terminus was found. The 
shortest natural ligand derived from gp160 was a 9-mer with canonical anchor 
motifs for Ld (15); the amino-terminal extended ligand 10-mer had all anchor 
motifs for Dd binding (16), (17). Both peptides were present in infected cells in 
similar amounts. The third peptidic species corresponded to a 15-mer peptide 
with an amino-terminal extension of six residues that probably protruded out of 
the Ld binding groove (18), and was recognized by CTL with an antigenicity only 
slightly lower than that of the optimal 9-mer but was more abundant in infected 
cells than this minimal 9-mer epitope. 
To test the “template” and the "molecular ruler" models, analysis of mouse 
aminopeptidase activity with the longest to date N-extending MHC class I 
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natural ligand recognized by CTL was carried out. Efficient trimming of the 
soluble peptide substrate to nonamer length was observed; the nonamer has 
the canonical anchor motif for binding to Ld and is the minimal natural ligand for 
the mouse H-2Ld molecule. In contrast, the six amino-terminal residues that 
most likely extended out of the MHC class I binding groove when the peptide-Ld 
complex was folded were not accessible to ERAAP activity.  
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MATERIALS AND METHODS 
 
Cell Lines and Antibodies (Ab) 
For stability assays, the TAP-deficient human lymphoblastoid T2 cells 
transfected with Ld was employed (19). This cell line was cultured in RPMI 1640 
supplemented with 10% fetal bovine serum and 5x10-5 M β-mercaptoethanol. 




Peptides were synthesized in a peptide synthesizer (model 433A; 
Applied Biosystems, Foster City, CA) and purified by Ion-Exchange-HPLC 
and/or RP-HPLC (purity > 99%, for an example see Supplementary Fig. 2, t = 0 
h) (18). Identities were confirmed by matrix-assisted laser desorption/ionization 
time of flight (MALDI-TOF) mass spectrometry. All peptide sequences are 
derived from the sequence 313KIRIQRGPGRAFVTI327 of the HIV-1 strain IIIB 
envelope glycoprotein. Peptides were named according to the first residue, the 
length, and the last residue. Thus, G9I refers to the nonamer of sequence 
319GPGRAFVTI327. The monosubstituted Ala analogues of HIV-1 peptides were 
named according to the substituted residue (Ala → Pro) and their position inside 
the HIV-1 peptide. Thus, A2-G9I refers to the nonamer of sequence 






Purified synthetic peptides K15I or R13I, Ld MHC class I heavy chain, 
and 2microglobulin were folded as previously described (21) followed by 
purification by the NIH Tetramer Core Facility (Emory University, Atlanta, GA, 
USA). In addition, an aliquot of these complexes were denatured by addition of 
trifluoroacetic acid to a final concentration of 0.1%, and the peptide identity was 
confirmed by both MALDI-TOF and electrospray-ion trap mass spectrometry. 
 
Digestion with recombinant ERAAP enzyme 
Recombinant purified mouse ERAAP enzyme (R&D Systems, 
Minneapolis, MN, USA) was incubated for the indicated periods at 37°C with 
purified synthetic peptide and/or H-2Ld-peptide complexes at the indicated 
molar enzyme/substrate ratios in 50 mM Tris, pH 7.4, and 1 mM DTT. The 
addition of trifluoroacetic acid to a final concentration of 0.1% stopped the 
digestions and denatured the proteins.  
 
MALDI-TOF mass spectrometry 
MALDI-TOF mass spectrometry was performed using a Reflex IV 
instrument (Brucker-Franzen Analytik, Bremen, Germany) operating in the 
positive ion reflection mode. The samples were dried, resuspended in 1 l of 
0.1% trifluoroacetic acid in a 2:1 solution of water:acetonitrile, and mixed with 1 
l of saturated -cyanohydroxycinnamic acid matrix in the same solution. One 
microliter of the mixture was dried and subjected to analysis.  
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 The intensity peaks obtained in each time point for all peptides were 
added up and this sum taken as 100% for each time point and depicted. Data 
shown are representative of 2-4 different experiments. 
 
 Electrospray-ion trap mass spectrometry  
Aliquots of total digestions were dried and dissolved in 10 l of 0.1% 
trifluoroacetic acid in water and sequenced by quadrupole ion trap microHPLC 
(Biobasic C18 column 150x0.18 mm, Thermo Electron, San Jose, CA, USA) 
electrospray MS/MS in a Deca XP LCQ mass spectrometer (Thermo Electron).  
The eluents used were as follows: A, 0.5% acetic acid in water; and B, 80% 
acetonitrile containing 0.5% acetic acid. The gradient was 0-40% B in 24 min, 
40-100% in 5 min, with a flow rate of 1.5 l/min. The MS/MS mode focused to 
each hypothetical parental peptide with an isolation width (m/z) of 1.5 Da was 
used (22), (23).  
MHC/peptide stability assay 
  TAP-deficient T2 cells transfected with Ld were cultured at 26oC, and 14 
h later they were washed and incubated for 2 h at 26oC with 500 μM of the 
different synthetic peptides, as described (24), (23). After washing, the cells 
were further incubated at 37oC. Aliquots removed at 60 min were stained with 
mAb 30-5-7S followed by flow cytometry. Cells incubated without peptide had 
peak fluorescence intensities close to background staining with second Ab 
alone. Fluorescence Index (FI) was calculated at each time point as the ratio of 
peak channel fluorescence of the sample to that of the control incubated without 
peptide. Data shown are the mean of 3 independent experiments. 
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RESULTS AND DISCUSSION 
 
ERAAP efficiently trims the natural soluble substrate 
 
In a previous study (18), a striking example of a nested set of three highly 
antigenic and similarly abundant natural MHC class I ligands of 15-, 10-, and 9-
aa in length and derived from a single HIV gp160 epitope was identified. To 
demonstrate that these three peptides are bound with identical register to H-2Ld 
molecules MHC/peptide complex stability assays using TAP-deficient cells 
transfected with Ld molecule were carried out. The exchange for alanine of the 
proline residue that serves as Ld canonical anchor motif abolished interaction 
with the MHC of the N-extended K15I and R10I peptides, as well as of G9I 
(Supplementary Fig. 1). This indicates that they bind to Ld molecule using the 
canonical anchors, and thus both K15I and R10I peptides protrude with an N-
terminus extending out of the Ld peptide groove. These data confirm our 
previous report about the nature of these interactions (18). 
To study susceptibility to aminopeptidase activity, recombinant ERAAP was 
incubated with K15I synthetic peptide, the same substrate detected in living 
murine cells. Subsequently, cleavage products generated after enzymatic 
digestion were analyzed by mass spectrometry at different times. At time 0 or in 
the absence of enzyme, this system allowed for the detection of molecular 
species with the same monoisotopic m/z as the K15I substrate (Supplementary 
Fig. 2, upper panel). Additionally, an ion 62 Daltons greater than the m/z of K15I 
(Supplementary Fig. 2, asterisk) and compatible with a molecular Cu+ adduct 
was detected. Na+ or K+ adducts were also found in some experiments 
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(Supplementary Fig. 2, 10m panel, asterisk). Minority peaks with K15I m/z less 
16 or 36 Daltons were frequently found (Supplementary Fig. 2, arrow), probably 
due to the neutral loss in the peptides under desorption/ionization conditions. 
After only 5 seconds in the presence of the enzyme, partial cleavage of the 
substrate was observed via detection of trimmed I14I and R13I products 
(Supplementary Fig. 2). In only 5 minutes, all of the substrate was converted 
into the R13I peptide, with small traces of R10I peptide starting to be 
detectable. After 10 minutes, traces of the shorter G9I peptide were also found. 
Finally, after 20 minutes of enzymatic reaction, significant detection of both G9I 
and R10I products was revealed. No signals were found at m/z values 
corresponding to I12I and Q11I peptides. 
To verify the species detected by MALDI-TOF experiments and to confirm 
their respective sequences, MS/MS analysis was performed via microHPLC 
with on-line detection by ESI-IT MS/MS. In this separation-detection system, the 
substrate and the four trimmed peptidic products (I14I, R13I, R10I, and G9I) 
were studied. The interpretation of the MS/MS fragmentation spectra allowed 
the unequivocal identification of all five peptides with the corresponding 
molecular ions detected by MALDI-TOF analysis (data not shown).  
The results shown in Supplementary Fig. 2 and other intermediate points are 
summarized and depicted in Fig. 1A for further clarification. The K15I substrate 
was quickly processed by mouse ERAAP to 14- and 13-aa products. The N-
terminal Arg of the 13mer peptide was rather resistant to trimming because the 
R13I peptide was virtually the only molecular species detected between 2.5 and 
15 min. The short R10I and G9I peptides appeared over 5-10 min of the 
reaction and were relevant in the reaction pool at 20 min. I12I and Q11I 
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intermediates were not detected. Thus, these two peptide intermediates must 
be processed quickly after R13I trimming.  
To study this enzymatic activity in more detail, similar experiments were 
performed with decreased enzyme concentration and increased reaction time. 
As shown Fig. 1B, the K15I substrate was detected for a longer period of time. 
The I14I and R13I peptides were present for shorter periods of time, as in 
Supplementary Fig. 2. R13I was the major product detected.  After 
approximately 1 hour of reaction, both R10I and G9I were present, and finally all 
of the substrate was trimmed to the G9I product. In summary, even with a 
slower reaction, peptide intermediates between R13I and R10I were not 
detected, indicating a fast conversion to R10I. This data is in agreement with 
the findings in infected living cells, where neither one can be detected (25), (18).  
Peptides shorter than G9I were not detected in the above experiments. To 
confirm this point, enzymatic reactions with larger amounts of ERAAP were 
performed. A pattern of appearance of trimmed products similar to that in 
previous experiments was observed (Fig. 1C) with one only difference: because 
of the increased reaction speed, all of the substrate was practically trimmed to 
the G9I product after 15 min. The reaction showed no change after the 30 min 
time point, and peptides shorter than the G9I nonamer were not detected. This 
finding is in agreement with a previous report (26) where this enzyme efficiently 
trims N-terminal residues of antigenic precursors unless they are flanked by 
proline and causes the accumulation of X-P-Xn peptides. Thus, mouse ERAAP 
is not able to trim the Gly-Pro bond of the G9I peptide (GPGRAFVTI). 
To exclude the possibility that lack of detection of intermediate and shorter 
peptides was due to different ionization efficiencies rather than to lack of 
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trimming products, titrations of peptides between 7 and 15 residues in length 
were analyzed by MALDI-TOF mass spectrometry. In the range studied 
(between 100 pmol and 1 ηmol), no differences were found among these 9 N-
extended peptides (data not shown). This is likely because they make up an N-
extended nested set of peptides with an identical C-end region; thus their 
ionization properties should be similar. 
In summary, mouse ERAAP efficiently trims the soluble K15I peptide to 
the minimal G9I peptide, a natural Dd and Ld ligand in infected cells (25), (18). 
Previous studies showed that the enzymatic activity of ERAAP in 
microsomes or living cells trims peptide precursors in a short time period 
(minutes) (27), (28), (29). In contrast, in vitro ERAAP was more inefficient 
because longer incubations are required with the recombinant or purified 
enzyme (in the order of hours) (7). This is also true for human ERAP enzymes 
trimming the same K15I precursor (10). The present study demonstrated 
significant ERAAP trimming of the K15I peptide in a very short time (seconds) 
and total substrate degradation in a few minutes. Some peptides can thus be 
trimmed in vitro with physiologic efficiency by ERAAP.  
ERAP1 is the human homologue of mouse ERAAP. Additionally, in 
humans but not mice, a second aminopeptidase, ERAP2, also trims certain 
precursors to MHC class I-presented antigenic peptides (30). The homology 
between the two human enzymes is less (~50% identity) than that between 
human ERAP1 and mouse ERAAP. ERAAP reproduced the activity of ERAP1 
on the 15-mer substrate (10), in agreement with their high degree of homology. 
 
H-2Ld molecule protects against in vitro trimming by aminopeptidase 
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Some authors have reported that MHC molecules may play a key role in 
contributing to generate the final peptide-MHC I complex (14). To test whether 
K15I could be trimmed while associated with the MHC class I presenting 
molecule, folded H-2Ld-K15I complexes were used as a possible substrate for 
ERAAP activity. As shown in Table 1 (upper panel), destruction of K15I peptide 
was not observed, and no trimming products were detected with high E/S ratios 
(ten fold higher than the quantity used in the experiment depicted in Fig. 2B). 
Similar results were obtained with lower E/S ratios (data not shown). 
To verify the activity of ERAAP, similar experiments with the K15I soluble 
peptide were carried out in parallel (Table 1, second panel). In this case, with an 
E/S ratio five fold less than that in the complexed substrate condition, 
substantial K15I disappearance and conversely emergence of aminoterminal 
cleavage products were detected.  
To rule out the possibility that absence of ERAAP trimming was the result 
of a nonspecific effect of some unknown component of the peptide-MHC 
complex preparation, a mix of soluble and complexed substrates was incubated 
in the presence of this mouse enzyme. As shown in Table 1 (third panel), 
efficient trimming of the K15I soluble peptide was found, and residual K15I 
amounts were detected (~3%) that were compatible with the total quantity of Ld-
K15I complex incubated in the reaction mix. In addition, to release K15I from 
the complex, in order to verify its integrity, Ld-K15I complex was denatured at 
pH=2, later equilibrated at pH=7 and this substrate was incubated with ERAAP. 
Similar trimming rate to the one observed with K15I soluble peptide was found 
(Table I, fourth panel). Also, ERAAP can trim soluble but not Ld-complexed 
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R13I peptide (Table I, lower panels). Collectively, these data excluded any 
general non-specific effect on ERAAP activity by the Ld-K15I complex 
preparation.  
Considering that (1) ERAAP trimming is very efficient with the soluble 15-
mer epitope and (2) yields the shorter R10I and overcoat G9I peptides, but (3) 
cannot trim the six N-terminally extended residues of K15I peptide in vitro when 
the peptide-MHC class I complex is fully folded, the two likely explanations for 
our previous (25), (18) and present results are the following. The K15I substrate 
is efficiently transported by murine TAP, as suggested by our previous study of 
transport to the ER (18). In the ER lumen, most of the substrate is quickly and 
efficiently folded within the H-2Ld molecules and thus protected from ERAAP 
activity. The remaining K15I molecules might be accessed by ERAAP and 
trimmed to R10I. A fraction of this peptide might be protected by either Dd or Ld 
molecules, and the rest might be trimmed to the final product G9I, which can 
also efficiently stabilize both MHC molecules. Alternatively, the three natural 
MHC class I ligands could be generated independently in the cytosol and 
transported to the ER lumen. There, in order to be protected from ERAAP 
trimming, both N-extended ligands would bind quickly to MHC class I molecules 
as their affinity is similar to that of the minimal epitope (25), (18). This second 
explanation is supported by the identification, in the natural Ld peptide mixtures 
resulting from the endogenous processing in infected cells, of only G9I, R10I 
and K15I natural ligands in contrast with the similar MHC binding affinities of 
nested set of synthetic peptides previously tested (G9I, R10I, Q11I, I12I, R13I 
and K15I) (18). 
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In summary, our data with a single epitope show that the H-2Ld molecule 
protects the HIV N-extended epitope from trimming by ERAAP. This indicates 
that ERAAP cannot trim the H-2Ld ligand when the peptide-MHC complex is 
fully folded, not complying with to the template model. Nevertheless, this model 
might still apply to this particular epitope if ERAAP would only trim the substrate 
bound to MHC when it is in the peptide-loading complex. But the existence of 
R10I natural ligand (that is not fully trimmed to minimal H-2Ld ligand, G9I) 
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Area charts of digestions performed with several E/S ratios. 
Soluble K15I synthetic peptide was digested with purified ERAAP. The intensity 
peaks obtained by MALDI-TOF analysis for all peptides in each time point were 
added up and this sum taken as 100% for each time point and depicted. The 
different products detected are named in their respective region. The E/S ratio 
























Comparison of trimming by ERAAP of soluble and/or 









      Enzyme 
Substrate c
0 ND d ND ND ND 100    
15 ND ND ND ND 100 Ld-K15I - 1:60 
30 ND ND ND ND 100    
60 ND ND ND ND 100    
90 ND ND ND ND 100    
0 ND ND ND ND 100    
0.08 ND ND 40 22 38 sK15I - 1:300 
5 4 11 45 17 23    
15 15 11 46 14 14    
0 ND ND ND ND 100    
0.08 ND ND 36 26 38 Ld-K15I + sK15I 4:96 1:300 
5 5 8 84 ND 3    
15 41 18 38 ND 3    
0 ND ND ND ND 100    
0.08 ND ND 33 24 43 dLd-K15I - 1:300 
5 5 30 49 13 3    
 
a The substrates used were Ld-complexed K15I (Ld-K15I), denatured Ld-complexed 
K15I (dLd-K15I) and soluble peptide (sK15I). 
b K15I-Ld/sK15I molar ratio. 
c Enzyme/substrate molar ratio. 
d ND, Not detected including Q11I and I12I peptides. 
